G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin and APC Mutation Cancer Research

Executive Summary: G007-LK is a highly selective and potent small-molecule inhibitor targeting tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with IC₅₀ values of 46 nM and 25 nM, respectively, suppressing poly(ADP-ribosyl)ation activity in vitro (APExBIO product data). In cellular models, G007-LK blocks Wnt/β-catenin signaling by stabilizing AXIN1/2 and promotes β-catenin degradation, leading to reduced tumor cell proliferation in APC-mutant colorectal cancer and hepatocellular carcinoma (Jia et al. 2017). In vivo studies confirm its antitumor efficacy with decreased TNKS1/2 and β-catenin protein levels in xenograft models. G007-LK’s solubility profile and handling parameters support reproducibility in cell-based and biochemical assays. Its validated mechanism and robust benchmarks position it as a reference tool for Wnt pathway and cancer biology research.

Biological Rationale

Tankyrases (TNKS1/2) are poly(ADP-ribose) polymerases involved in Wnt/β-catenin signaling, telomere maintenance, glucose metabolism, and cell cycle regulation (Jia et al. 2017). Dysregulation of tankyrase activity is implicated in tumorigenesis, particularly in colorectal cancer with APC mutations and in hepatocellular carcinoma, where tankyrase expression is elevated. The Wnt/β-catenin pathway is critical for cell proliferation and stem cell maintenance. Constitutive activation, commonly via APC mutation, leads to β-catenin accumulation and oncogenic transcription. Tankyrase inhibitors like G007-LK disrupt this axis by stabilizing AXIN1/2, scaffolding proteins that promote β-catenin degradation, and by influencing Hippo pathway signaling via AMOTL1/2 stabilization.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK acts as a competitive, small-molecule inhibitor of TNKS1/2, binding to the catalytic PARP domain and blocking auto-poly(ADP-ribosyl)ation. This inhibition stabilizes AXIN1/2, leading to formation of β-catenin "degradasomes" with β-TrCP and ubiquitin, resulting in efficient β-catenin proteasomal degradation. In Wnt3a-induced HEK 293 cells, G007-LK inhibits Wnt signaling reporter ST-Luciferase with an IC₅₀ of 0.05 μM. In APC-mutant colorectal cancer cells (e.g., SW480), it reduces cytosolic and nuclear β-catenin, suppressing Wnt target gene expression. In hepatocellular carcinoma, G007-LK downregulates YAP by stabilizing AMOTL1/2, negative regulators that prevent YAP nuclear translocation (Jia et al. 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively (APExBIO).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses ST-Luciferase reporter with IC₅₀ = 0.05 μM under serum-free conditions (APExBIO).
• In SW480 APC-mutant colorectal cancer cells, G007-LK induces dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, reducing β-catenin protein levels (bi10773.com).
• In vivo, G007-LK inhibits tumor growth and reduces TNKS1/2 and β-catenin in COLO-320DM xenograft mouse models (hbcag-hepatitis-b-virus.com).
• In hepatocellular carcinoma cell lines, G007-LK reduces cell proliferation and downregulates YAP and Wnt targets by stabilizing AMOTL1/2 proteins (Jia et al. 2017).

This article extends prior summaries such as this mechanism review by integrating updated benchmark data and workflows for reproducible use. It also clarifies scenario-driven troubleshooting discussed in this practical guide, ensuring application in both Wnt/β-catenin and Hippo pathway contexts.

Applications, Limits & Misconceptions

G007-LK is primarily used in research on Wnt/β-catenin and Hippo pathway signaling, APC mutation colorectal cancer, and hepatocellular carcinoma. It supports studies of β-catenin degradation, AXIN1/2 stabilization, and poly(ADP-ribosyl)ation inhibition. Limitations include solubility constraints (insoluble in water and ethanol), and selectivity for tankyrase 1/2 over other PARP family members. Data suggest limited efficacy in tumors not driven by Wnt/β-catenin or YAP signaling deregulation.

Common Pitfalls or Misconceptions

• G007-LK is not effective in cancers without Wnt/β-catenin or Hippo pathway activation (Jia et al. 2017).
• It does not inhibit other PARPs involved in DNA repair; selectivity is specific to TNKS1/2 (APExBIO).
• Long-term storage of G007-LK solution can reduce potency; solid storage at -20°C is required (APExBIO).
• Improper solubilization (using water or ethanol) leads to precipitation; DMSO at ≥26.5 mg/mL is recommended (APExBIO).
• G007-LK is not approved for clinical use; research use only (APExBIO).

Workflow Integration & Parameters

G007-LK (SKU B5830, from APExBIO) is supplied as a solid, recommended for storage at -20°C. For experimental use, dissolve in DMSO to ≥26.5 mg/mL. Warm the solution to 37°C or use an ultrasonic bath for optimal solubility. Avoid water and ethanol as solvents. Prepare fresh solutions for each experiment to maintain activity. Use in cell-based assays at validated nanomolar concentrations (e.g., 0.05 μM for Wnt reporter inhibition; up to 1 μM for cell proliferation assays). For in vivo studies, refer to published protocols for formulation and dosing (Jia et al. 2017). For troubleshooting and advanced workflow scenarios, see the scenario-driven guide (hbcag-hepatitis-b-virus.com), which this article updates with new evidence and usage tips.

Conclusion & Outlook

G007-LK tankyrase 1/2 inhibitor provides a validated, highly selective tool for dissecting Wnt/β-catenin and Hippo pathway signaling in cancer research, with robust activity in APC mutation colorectal cancer and hepatocellular carcinoma models. Its nanomolar efficacy, defined mechanism, and workflow-friendly handling make it a reference standard for β-catenin degradation and pathway inhibition studies. While not a clinical compound, G007-LK (available from APExBIO) accelerates mechanistic discovery and preclinical modeling, supporting further innovation in cancer biology. For a focused summary on its application in specific pathway models, see this advanced research overview, which this article extends by providing detailed benchmarks and troubleshooting integration.